RxDoctor Payments Data

Hannah Katz, APRN

Nurse Practitioner · Omaha, NENPI 1356939201

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,096 of the $5,979 with a category attached, or 85.2%. It is spread thinly across 39 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,646, more than ten times the $14 reported in 2021. Among nurse practitioner clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,979in general payments, 2019–2025

Across 197 payments — averaging $30.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AstraZeneca$709
  • E.r. Squibb & Sons, L.L.C.$437
  • Bayer$421
  • Boehringer Ingelheim$392
  • Novartis$382
  • plus $2K from 33 others

What the payments were for

  • Travel & lodging$80313%
  • Food & beverage$5,09685%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,979 in reported general payments places this provider in the 95th percentile of 924 nurse practitioner providers in Nebraska.

See all nurse practitioner providers in Nebraska

Medicare billing

Part B allowed, 2024
$32,745
Medicare patients
276
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban20$16,979
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$1,114
Gabapentin22$418
Atorvastatin Calcium21$389
Amiodarone Hcl11$351
ClopidogrelClopidogrel Bisulfate13$314
Metoprolol Succinate30$287
Montelukast Sodium16$281
Albuterol Sulfate HfaAlbuterol Sulfate11$228
Rosuvastatin Calcium18$210
Furosemide25$122
Hydrochlorothiazide18$113
Losartan Potassium12$106
Cyclobenzaprine Hcl15$101
Sertraline Hcl18$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$188$16,97920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 924 nurse practitioner providers in Nebraska.

Other nurse practitioner in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →